Cargando…

Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA

Mucopolysaccharidosis type IIIA (MPS-IIIA) is a lysosomal storage disorder (LSD) caused by inherited defect of sulfamidase, a lysosomal sulfatase. MPS-IIIA is one of the most common and severe forms of LSDs with CNS involvement. Presently there is no cure. Here we have developed a new gene delivery...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorrentino, Nicolina Cristina, Cacace, Vincenzo, De Risi, Maria, Maffia, Veronica, Strollo, Sandra, Tedesco, Novella, Nusco, Edoardo, Romagnoli, Noemi, Ventrella, Domenico, Huang, Yan, Liu, Nan, Kalled, Susan L., Choi, Vivian W., De Leonibus, Elvira, Fraldi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881609/ https://www.ncbi.nlm.nih.gov/pubmed/31788497 http://dx.doi.org/10.1016/j.omtm.2019.10.009

Ejemplares similares

Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA
por: Sidhu, Navdeep S., et al.
Publicado: (2014)

Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy
por: Chen, Yonghong, et al.
Publicado: (2018)

Retinal Degeneration in MPS-IIIA Mouse Model
por: Intartaglia, Daniela, et al.
Publicado: (2020)

A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA
por: Sorrentino, Nicolina Cristina, et al.
Publicado: (2013)

The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease
por: Monaco, Antonio, et al.
Publicado: (2020)

The Amyloid Inhibitor CLR01 Relieves Autophagy and Ameliorates Neuropathology in a Severe Lysosomal Storage Disease
por: Monaco, Antonio, et al.
Publicado: (2022)

Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice
por: Gustavsson, Susanne, et al.
Publicado: (2019)

Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases
por: Sambri, Irene, et al.
Publicado: (2016)

From hypertransaminasemia to mucopolysaccharidosis IIIA
por: Krawiec, Paulina, et al.
Publicado: (2014)

Prediction of phenotypic severity in mucopolysaccharidosis type IIIA
por: Knottnerus, Suzan J. G., et al.
Publicado: (2017)

Bioinformatics classification of mutations in patients with Mucopolysaccharidosis IIIA
por: Tanwar, Himani, et al.
Publicado: (2019)

Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA
por: Anson, Donald S, et al.
Publicado: (2007)

Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB
por: Wilkinson, Fiona L., et al.
Publicado: (2012)

Distribution of Heparan Sulfate Oligosaccharides in Murine Mucopolysaccharidosis Type IIIA
por: Mason, Kerryn, et al.
Publicado: (2014)

Neurocognitive testing in a murine model of mucopolysaccharidosis type IIIA
por: Pericleous, Kleopatra, et al.
Publicado: (2023)

Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
por: Bugiani, Marianna, et al.
Publicado: (2023)

An immune deficient mouse model for mucopolysaccharidosis IIIA (Sanfilippo syndrome)
por: Pollock, Kari, et al.
Publicado: (2023)

Cardiac disease as the presenting feature of mucopolysaccharidosis type IIIA: A case report
por: Ribeiro, Erlane Marques, et al.
Publicado: (2014)

A novel mutation of SGSH and clinical features analysis of mucopolysaccharidosis type IIIA
por: Li, Xiaohua, et al.
Publicado: (2018)

Sensory-motor behavioral characterization of an animal model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI)
por: Saccone, Paola, et al.
Publicado: (2014)

Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse
por: Paget, Tamara L., et al.
Publicado: (2021)

Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease
por: Alliegro, Marialuisa, et al.
Publicado: (2016)

Impaired parkin-mediated mitochondrial targeting to autophagosomes differentially contributes to tissue pathology in lysosomal storage diseases
por: de Pablo-Latorre, Raquel, et al.
Publicado: (2012)

Female Mucopolysaccharidosis IIIA Mice Exhibit Hyperactivity and a Reduced Sense of Danger in the Open Field Test
por: Langford-Smith, Alex, et al.
Publicado: (2011)

A Multiparametric Computational Algorithm for Comprehensive Assessment of Genetic Mutations in Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome)
por: Ugrinov, Krastyu G., et al.
Publicado: (2015)

Haematopoietic stem cell gene therapy with IL‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA
por: Parker, Helen, et al.
Publicado: (2020)

Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector
por: Bobo, Tierra A., et al.
Publicado: (2020)

Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction
por: Magat, Jenna, et al.
Publicado: (2022)

Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches
por: Fraldi, Alessandro, et al.
Publicado: (2018)

Impact of chemical modification of sulfamidase on distribution to brain interstitial fluid and to CSF after an intravenous administration in awake, freely-moving rats
por: Janson, Juliette, et al.
Publicado: (2019)

Non-clinical Safety and Efficacy of an AAV2/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI
por: Ferla, Rita, et al.
Publicado: (2017)

Insulin Receptor Antibody–Sulfamidase Fusion Protein Penetrates the Primate Blood–Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type A Cells
por: Boado, Ruben J., et al.
Publicado: (2014)

Pre-clinical Safety and Efficacy of Lentiviral Vector-Mediated Ex Vivo Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis IIIA
por: Ellison, Stuart M., et al.
Publicado: (2019)

Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: A case description and comparison with a genotype-matched control group
por: Köhn, Anja F., et al.
Publicado: (2020)

Disease Rescue and Increased Lifespan in a Model of Cardiomyopathy and Muscular Dystrophy by Combined AAV Treatments
por: Vitiello, Carmen, et al.
Publicado: (2009)

Hearing Loss in Mucopolysaccharidosis
por: Bicalho, Cibele Gomes, et al.
Publicado: (2021)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

AAV-mediated transcription factor EB (TFEB) gene delivery ameliorates muscle pathology and function in the murine model of Pompe Disease
por: Gatto, Francesca, et al.
Publicado: (2017)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Ionic liquids IIIA
por: Rogers, Robin D, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_uf59a2608e9bh80no4e2iovhpg